Development of in vitro and ex vivo models for testing of new therapeutic options in HNSCC
Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S239
DOI: 10.1055/s-0044-1784783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Ines Ugele und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Infiltration, differentiation and function of immune cells are crucial for an effective anti-tumour immune response. The metabolic tumour microenvironment decisively shapes the function and polarisation of infiltrating immune cells and thus represents a potential therapeutic target structure. Valid ex vivo and in vitro models reflecting this complex interplay are essential to identify possible therapeutic strategies. Material/Methods We established a co-culture protocol of HNSCC spheroids with whole immune cell populations from peripheral blood for testing metabolic conditions or pharmacological modulators. For the transfer to the patient situation we developed an ex vivo model of freshly obtained tumour tissue cultivated in autologous serum to test various metabolic conditions and clinically applicable metabolic modulators. The tissue was processed to a single cell suspension and the immune infiltrate and function analysed.
Results
As observed in primary tumours, glutamine restriction diminished T cell function; accordingly, treatment with the glutaminase inhibitor BPTES increased IFNγ production in a portion of patients. In addition, a partial reduction in the tumour-promoting cytokine IL-6 was observed. In contrast, treatment with the glutamine analogue DON, shown to positively impact anti-tumor response of T cells in mice, had a negative effect on human intra-tumoral T cell function.
Conclusion
We were able to establish an in vitro tumour spheroid and ex vivo tumour fragment model for HNSCC in which effects of metabolic manipulation on tumour and immune cells can be tested. The ex vivo model is to be expanded by the addition of autologous immune cells in order to analyse effects on infiltration. Funding information Wilhelm Sander-Stiftung; Else-Kröner-Fresenius-Stiftung Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Ugele, I., Wehrstein, M., Korf, C., Zierul, T., Bohr, C., Bohr, K., & Decking, S. (2024). Development of in vitro and ex vivo models for testing of new therapeutic options in HNSCC. Laryngo-Rhino-Otologie, 103(S 02 S 02), S239. https://doi.org/10.1055/s-0044-1784783
Vancouver
Ugele I, Wehrstein M, Korf C, Zierul T, Bohr C, Bohr K, et al. Development of in vitro and ex vivo models for testing of new therapeutic options in HNSCC. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S239. doi:10.1055/s-0044-1784783
BibTeX
@article{Ugele2024,
author = {Ugele, Ines and Wehrstein, Monika and Korf, Clarissa and Zierul, Torunn and Bohr, Christopher and Bohr, Kathrin and Decking, Sonja},
title = {Development of in vitro and ex vivo models for testing of new therapeutic options in HNSCC},
journal = {Laryngo-Rhino-Otologie},
year = {2024},
volume = {103},
number = {S 02 S 02},
pages = {S239},
doi = {10.1055/s-0044-1784783}
}
EUVIMED